What is Amneal Pharmaceuticals, Inc.'s market cap?

Amneal Pharmaceuticals, Inc. (AMRX) has a market capitalization of $5.8B and trades on NASDAQ.

What is Amneal Pharmaceuticals, Inc.'s revenue and profitability?

Amneal Pharmaceuticals, Inc. generated $3.0B in trailing twelve-month revenue with net income of $122.1M, representing a net margin of 4.0%. Gross margin stands at 38.7%, with free cash flow of $240.8M. These figures are based on the Q1 2026 filing.

Who are Amneal Pharmaceuticals, Inc.'s competitors?

Amneal Pharmaceuticals, Inc.'s key competitors include AbbVie Inc., Viatris Inc., McKesson Corporation, and others. These companies compete in similar markets and product categories.

Who does Amneal Pharmaceuticals, Inc. partner with?

Amneal Pharmaceuticals, Inc.'s notable partners include mAbxience S.L., Valorum Oncology, LLC, Kashiv Biosciences LLC, and others.

What subsidiaries does Amneal Pharmaceuticals, Inc. have?

Amneal Pharmaceuticals, Inc.'s subsidiaries include AvKARE.

Where is Amneal Pharmaceuticals, Inc. headquartered?

Amneal Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 7,700 people. It has been publicly traded since 2018.

Amneal Pharmaceuticals, Inc.

AMRX

Amneal Pharmaceuticals is a vertically integrated pharmaceutical company that develops, manufactures, and distributes a diverse portfolio of generic, biosimilar, and proprietary branded medicines.

Market cap

$5.78B+128%

Revenue$3.0B+7.6%

Net income$122.1M+1,036%

Free cash flow$240.8M-4.1%

EPS (diluted)$0.38+1,050%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$722.5MBeat by $2.9M EPS$0.27Beat by $0.10

Read the full report

Next report

Jul 30, 2026 (Tomorrow)

Revenue estimate$768.2M

EPS estimate$0.24

Financials

Q1 2026

Income statement

See full

Revenue$722.5M+3.9%

Gross profit$320.1M+25.1%

Operating income$141.8M+41.3%

Net income$62.3M+411%

EPS (diluted)$0.19+375%

Balance sheet

See full

Cash & equivalents$197.7M+234%

Total debt$2.6B+17.7%

Total equity-$45.4M+65.5%

Total assets$3.5B+5.2%

Cash flow

See full

Operating cash flow-$26.7M-461%

CapEx$8.2M-37.9%

Free cash flow-$34.9M-507%

Valuation & ratios

Valuation

See full

Market cap$5.78B+128%

Enterprise value$8.15B+74.7%

P/E47.3×-711×

P/S1.9×+1.0×

Profitability

See full

Gross margin38.7%+2.0pp

Operating margin14.3%+1.6pp

Net margin4%+3.6pp

FCF margin7.9%-1.0pp

Returns & leverage

See full

Current ratio2.5×+1.1×

Segments

By product

See full

Subtotal dosage forms$417.9M+1.1%

Oral solid$171.1M-4.4%

Subtotal therapeutic classes$133.3M+23.1%

Distribution$89.1M-15.0%

Central nervous system$83.4M+23.3%

By segment

See full

AvKARE$166.0M-3.7%

Specialty$133.3M+23.1%

Competitors

By market cap

Cardinal Health$53.7B+44.0%

Viatris$20.5B+89.0%

Jazz Pharmaceuticals$16.0B+126%

Amneal Pharmaceuticals, Inc.$5.8B+126%

By revenue growth

Cardinal Health+12.8%

McKesson+12.4%

AbbVie+9.5%

Jazz Pharmaceuticals+9.2%

Amneal Pharmaceuticals, Inc.+7.6%

Cencora+5.9%

Viatris+1.6%

Pfizer+1.4%

By net margin

Pfizer15.65%+6.3pp

AbbVie5.79%-1.5pp

Amneal Pharmaceuticals, Inc.4.01%+4.5pp

McKesson1.18%+0.3pp

Cardinal Health0.62%-0.1pp

Cencora0.599%+0.6pp

Viatris-2.04%+24.4pp

Jazz Pharmaceuticals-8.86%-19.8pp

Profile

Amneal Pharmaceuticals is a vertically integrated pharmaceutical company that develops, manufactures, and distributes a diverse portfolio of generic, biosimilar, and proprietary branded medicines. The company focuses on complex drug formulations and high-barrier-to-entry products across various dosage forms, including oral solids, injectables, and respiratory therapies. Its value proposition centers on providing affordable medicine alternatives while maintaining a specialized presence in central nervous system and endocrine disorders.

Competitive position

A leading provider of complex generics and biosimilars with a vertically integrated supply chain and a growing proprietary specialty brand portfolio.

GeographiesUnited States, India, Ireland, Puerto Rico

Customer segmentsGovernment Agencies, Healthcare Providers, Retail Pharmacies, Hospitals

Business modelManufacturing, Wholesale Distribution, Research and Development, Licensing

SuppliersActive Pharmaceutical Ingredient (API) suppliers, Bulk pharmaceutical chemical manufacturers, Third-party contract manufacturers

CustomersPharmaceutical wholesalers, Large retail chains, Group Purchasing Organizations, Government healthcare departments

CountryUnited States of America

Listed2018

Employees7.7K

CEOChirag K. Patel

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websiteamneal.com

FilingsSEC EDGAR

Ask your AI about Amneal Pharmaceuticals, Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s market cap?: Amneal Pharmaceuticals, Inc. (AMRX) has a market capitalization of $5.8B and trades on NASDAQ.
What is Amneal Pharmaceuticals, Inc.'s revenue and profitability?: Amneal Pharmaceuticals, Inc. generated $3.0B in trailing twelve-month revenue with net income of $122.1M, representing a net margin of 4.0%. Gross margin stands at 38.7%, with free cash flow of $240.8M. These figures are based on the Q1 2026 filing.
Who are Amneal Pharmaceuticals, Inc.'s competitors?: Amneal Pharmaceuticals, Inc.'s key competitors include AbbVie Inc., Viatris Inc., McKesson Corporation, and others. These companies compete in similar markets and product categories.
Who does Amneal Pharmaceuticals, Inc. partner with?: Amneal Pharmaceuticals, Inc.'s notable partners include mAbxience S.L., Valorum Oncology, LLC, Kashiv Biosciences LLC, and others.
What subsidiaries does Amneal Pharmaceuticals, Inc. have?: Amneal Pharmaceuticals, Inc.'s subsidiaries include AvKARE.
Where is Amneal Pharmaceuticals, Inc. headquartered?: Amneal Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 7,700 people. It has been publicly traded since 2018.